Talk:Binimetinib

NDA submitted June 2016
Array Bio submits marketing application in U.S. for lead product candidate in certain type of melanoma says "Array BioPharma files a New Drug Application (NDA) with the FDA seeking approval of ... binimetinib for the treatment [of] NRAS mutation-positive melanoma. [based on] the Phase 3 NEMO study which showed an improvement in progression-free survival versus the chemo agent dacarbazine." - Rod57 (talk) 11:03, 5 July 2016 (UTC)